Note B - Going Concern and Liquidity
|12 Months Ended|
Dec. 31, 2018
|Notes to Financial Statements|
|Substantial Doubt about Going Concern [Text Block]||
NOTE B- GOING CONCERN AND LIQUIDITY
In accordance with Accounting Standard Codification (“ASC”)
40,“Presentation of Financial Statements – Going Concern”, the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within
oneyear after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year since its inception. At
December 31, 2018,the Company’s cash on hand and net current assets decreased to
2017,respectively. Based on the expected cash needed for operating activities, the Company’s current cash and liquidity including the
February 2019financing is
notsufficient to finance the operating requirements for at least the next
12months from the filing date. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.
Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company’s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever. Management is actively pursuing financing or other strategic plans but can provide
noassurances that such financing or other strategic plans will be available on acceptable terms, or at all.
February 2019,Milestone Scientific consummated a public and private offering of Common Stock. The public offering generated gross proceeds of approximately
$2.0million through the issuance of
5,715,000shares of common stock and warrants of
1,428,000to purchase common shares. Subsequent to the public offering, the underwriter exercised its overallotment option and paid approximately
567,400additional shares. See Note T.
February 2019,the Company generated gross proceeds from a private offering of approximately
$250,000through the issuance of
714,286shares of common stock and warrants of
178,594to purchase common shares to
Bp4S.p.A., a principal stockholder of Milestone Scientific, that exercised its right to participate on a prorated basis in the recent public offering.
Bp4’sCEO is a director of Milestone Scientific and also Chief Executive Officer and Director of Wand Dental, a wholly owned subsidiary of Milestone Scientific. See Note T.
These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do
notinclude any adjustments to reflect the possible future effects on the recover ability and classification of assets or the amounts and classification of liabilities that
mayresult from the inability of the Company to continue as a going concern.
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef